Abstract
INTRODUCTION & OBJECTIVES: Neoadjuvant cisplatin based chemotherapy is recommended for patients with muscle invasive bladder cancer. Cisplatin based regimes have similar efficacy with complete response in 30% a survival advantage if 16% (HR, 0.84;CI 0.72 to 0.99). The ability to identify a biomarker which is able to predict response to treatment would increase pathological complete response rates and spare nonresponders adverse events of chemotherapy. DNA hypermethylation has been implicated in chemotherapy resistance in cancers. We hypothesised that DNA methylation may not only represent the mechanisms for the acquisition of resistance, but may also be a potential biomarker to predict response to platinum based chemotherapy in bladder cancer.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
